Journal
PRIMARY CARE DIABETES
Volume 14, Issue 5, Pages 558-563Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.pcd.2020.06.010
Keywords
SARS-CoV-2; COVID-19; Diabetes mellitus
Categories
Funding
- MSD
- AstraZeneca
- Sanofi
- Novo Nordisk
- Eli Lilly
- Boehringer-Ingelheim
- Novartis
- Pfizer
- GSK
- Trigocare
- Libytec
- Valeant
- Servier
- ELPEN
- Lilly
- Bayer
- Amgen
Ask authors/readers for more resources
COVID-19 and diabetes are currently two global pandemics. Epidemiological studies indicate that diabetes is the second most common comorbidity in COVID-19. This review aims to summarize currently available data about prevalence, possible pathophysiological mechanisms and management of patients with diabetes and COVID-19. (C) 2020 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
